3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Stomatitis
2
Mucositis
2
Pain, Postoperative
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Melanoma
1
Lung Neoplasms
1
Head and Neck Neoplasms
1
Esophageal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Anastomotic Leak
1
Interventions
Carboplatin
358
Pemetrexed
275
Cisplatin
229
Paclitaxel
212
Docetaxel
205
Gemcitabine
160
Erlotinib Hydrochloride
150
Bevacizumab
132
pembrolizumab
128
Radiotherapy
112
Nivolumab
88
durvalumab
84
Drug Therapy
84
osimertinib
81
atezolizumab
58
Vinorelbine
53
Gefitinib
53
Radiosurgery
49
Cetuximab
39
Taxes
37
130-nm albumin-bound paclitaxel
35
Ipilimumab
34
anlotinib
33
Surgical Procedures, Operative
33
Magnetic Resonance Spectroscopy
33
Etoposide
30
Albumin-Bound Paclitaxel
29
tislelizumab
27
icotinib
27
Specimen Handling
26
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Carcinoma, Non-Small-Cell Lung
×
Water
×
Clear all
NCT04863248
2023-04-14
PRESERVE 4
G1 Therapeutics, Inc.
Phase 2
Terminated
10 enrolled
14 charts